Search Results

Impact of Delay to Angioplasty on ACS Patients Studied

April 6, 2010—Paul Sorajja, MD, et al have published an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial that aimed to determine the impact of delay to angioplasty on patients with acute coronary syndromes.

Findings Published From United States Postmarket Registry of Abbott Vascular's MitraClip for TMVR

March 7, 2016—Findings from the United States postapproval registry of the MitraClip transcatheter mitral valve repair (TMVR) system (Abbott Vascular) were published by Paul Sorajja, MD, et al in the Journal of the American College of Cardiology (JACC, 2016;67:1129–1140).

One-Year Data Presented for Abbott Vascular's MitraClip TMVR System

March 18, 2017—Abbott Vascular announced 1-year outcomes from the United States study of real-world experience for the company's MitraClip transcatheter mitral valve repair (TMVR) system to treat patients with degenerative mitral regurgitation (DMR).

Findings Published From Global Feasibility Study of Abbott's Tendyne TMVR Device

March 26, 2019—The Minneapolis Heart Institute Foundation (MHIF) announced the publication of data from a global feasibility study of transcatheter mitral valve replacement (TMVR) with the investigational Tendyne valve technology (Abbott Structural Heart).

Early Outcomes Presented for Medtronic's Intrepid TMVR System

November 1, 2017—Medtronic announced the presentation of data for its self-expanding Intrepid transcatheter mitral valve replacement (TMVR) system in patients with severe, symptomatic mitral valve regurgitation.

Gore Acquires Pipeline Medical Technologies, Inc.

September 6, 2018—Gore & Associates announced the acquisition of Pipeline Medical Technologies, Inc., which is a privately held medical technology company focused on advancing chordal repair for degenerative mitral regurgitation via a transcatheter procedure.

SUMMIT-MAC Evaluates Abbott’s Tendyne TMVR System for Severe Mitral Annular Calcification

October 27, 2025—New findings from the SUMMIT-MAC study show that transcatheter mitral valve replacement (TMVR) with the Tendyne system (Abbott) led to successful treatment of severe mitral annular calcification (MAC) in approximately all patients, along with significant improvements in heart failure symptoms and quality-of-life parameters.

TRILUMINATE Pivotal Trial Reports 1-Year Outcomes With Abbott's TriClip to Treat Tricuspid Regurgitation

March 4, 2023—The American College of Cardiology announced that the TRILUMINATE Pivotal trial of the TriClip device (Abbott) demonstrated that in patients with a poorly functioning tricuspid heart valve, using the device to repair the valve was safe and improved both the valve’s functioning and patients’ quality of life at 1 year compared with the best available medical therapy.

Abbott’s TriClip TEER System Approved by FDA to Treat Tricuspid Regurgitation

April 2, 2024—Abbott announced that the FDA has approved the company’s TriClip transcatheter edge-to-edge repair (TEER) system, which is designed for the treatment of tricuspid regurgitation (TR).

TRILUMINATE Trial Begins for Abbott Vascular's Transcatheter Tricuspid Valve Repair System

August 11, 2017—Abbott Vascular announced that the first patient has been enrolled in the TRILUMINATE clinical study to evaluate the company's clip-based transcatheter tricuspid valve repair (TTVR) system for treating patients with moderate or severe tricuspid regurgitation.

TRILUMINATE Pivotal Trial Begins for Abbott's TriClip Transcatheter Tricuspid Valve Repair System

September 5, 2019—Abbott announced the commencement of the TRILUMINATE pivotal trial to evaluate the safety and effectiveness of the company’s TriClip transcatheter tricuspid valve repair system for the treatment of severe tricuspid regurgitation (TR).

Abbott’s Tendyne TMVR System Approved by FDA

May 27, 2025—Abbott announced FDA approval of the company’s Tendyne transcatheter mitral valve replacement (TMVR) system for the treatment of mitral valve disease.

4C Medical’s ATLAS Pivotal Trial of AltaValve TMVR System Commences Enrollment

October 14, 2024—4C Medical Technologies, Inc. recently announced it has commenced enrollment in the ATLAS pivotal trial in Europe and United States.

FDA Approves Expansion of Ancora Heart's Feasibility Study for the AccuCinch System

May 14, 2018—Ancora Heart, Inc. announced that the US Food and Drug Administration has approved the expansion of the company’s United States feasibility study that is evaluating the investigational AccuCinch ventricular repair system designed for the treatment of heart failure and functional mitral regurgitation (FMR).